Affiliation:
1. University of Torino
2. Università del Piemonte Orientale
3. University of Pavia
Abstract
Abstract
This study aims to develop poly lactic-co-glycolic acid (PLGA) nanoparticles with an innovative imaging-guided approach based on Boron Neutron Capture Therapy for the treatment of mesothelioma. The herein-reported results demonstrate that PLGA nanoparticles incorporating oligo-histidine chains and the dual Gd/B theranostic agent AT101 can successfully be exploited to deliver a therapeutic dose of boron to mesothelioma cells, significantly higher than in healthy mesothelial cells as assessed by ICP-MS and MRI. The selective release is pH responsive taking advantage of the slightly acidic pH of the tumour extracellular environment and triggered by the protonation of imidazole groups of histidine. After irradiation with thermal neutrons, tumoral and healthy cells survival and clonogenic ability were evaluated. Obtained results appear very promising, providing patients affected by this rare disease with an improved therapeutic option, exploiting PLGA nanoparticles.
Publisher
Research Square Platform LLC
Reference42 articles.
1. Baas Malignant pleural mesothelioma: the standard of care and challenges for future management Crit;Meerbeeck JP;Rev. Oncol. Hematol,2011
2. Stella Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic Eur;Røe OD;Respir. Rev.,2015
3. Vermaelen Biomarkers for early diagnosis of malignant mesothelioma: do we need another moonshot?;Lagniau S;Oncotarget,2017
4. Imai HEG1 is a novel mucin-like membrane protein that serves as a diagnostic and therapeutic target for malignant mesothelioma Sci;Tsuji S;Rep.,2017
5. Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP;Dubois F;Target Oncol,2022